ArticleCellular oncology (Dordrecht, Netherlands)2012
Analytical sensitivity and stability of DNA methylation testing in stool samples for colorectal cancer detection.
Article in Cellular oncology (Dordrecht, Netherlands), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 30 citations in OpenAlex.
- Genetic and Epigenetic Biomarkers of Immune Checkpoint Blockade Response.Journal of clinical medicine · 2020Review
- Fecal Genetic Mutations and Human DNA in Colorectal Cancer and Polyps Patients.Asian Pacific journal of cancer prevention : APJCP · 2019Article
- Evaluating gut microbiota profiles from archived fecal samples.BMC gastroenterology · 2018Article
- A new approach to epigenome-wide discovery of non-invasive methylation biomarkers for colorectal cancer screening in circulating cell-free DNA using pooled samples.Clinical epigenetics · 2018Article
- DNA Methylation as a Noninvasive Epigenetic Biomarker for the Detection of Cancer.Disease markers · 2017Review
- Detection of SNCA and FBN1 methylation in the stool as a biomarker for colorectal cancer.Disease markers · 2015Article
- Detection of miR-34a and miR-34b/c in stool sample as potential screening biomarkers for noninvasive diagnosis of colorectal cancer.Medical oncology (Northwood, London, England) · 2014Article
- Emerging evidence for CHFR as a cancer biomarker: from tumor biology to precision medicine.Cancer metastasis reviews · 2014Review
- Detection of hypermethylated fibrillin-1 in the stool samples of colorectal cancer patients.Medical oncology (Northwood, London, England) · 2013Article
- Comparative DNA methylation among females with neurodevelopmental disorders and seizures identifies TAC1 as a MeCP2 target gene.Journal of neurodevelopmental disorders · 2013Article
- Detection of hypermethylated spastic paraplegia-20 in stool samples of patients with colorectal cancer.International journal of medical sciences · 2013Article
- DNA methylation analysis of secreted frizzled-related protein 2 gene for the early detection of colorectal cancer in fecal DNA.Nigerian medical journal : journal of the Nigeria Medical AssociationArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundStool-based molecular tests hold large potential for improving colorectal cancer screening. Here, we investigated the analytical sensitivity of a DNA methylation assay on partial stool samples, and estimated the DNA degradation in stool over time. In addition, we explored the detection of DNA methylation in fecal immunochemical test (FIT) fluid. MATERIALS AND
methodsPartial stool samples of colonoscopy-negative individuals were homogenized with stool homogenization buffer, spiked with different numbers of HCT116 colon cancer cells and kept at room temperature for 0, 24, 48, 72 and 144 h before DNA isolation. Analytical sensitivity was determined by the lowest number of cells that yielded positive test results by DNA methylation or mutation analysis. DNA methylation in FIT fluid was measured in 11 CRC patients and 20 control subjects.
resultsThe analytical sensitivity for detecting DNA methylation was 3000 cells per gram stool, compared to 60000 cells per gram stool for detection of DNA mutations in the same stool samples. No degradation up to 72 h was noted when a conservation buffer was used. DNA methylation was detected in 4/11 CRC FIT samples and in none of the 20 control FIT samples.
conclusionsMethylation based stool DNA testing showed a high analytical sensitivity for tumor DNA in partial stool samples, which was hardly influenced by DNA degradation over time, provided an adequate buffer was used. The feasibility of detecting DNA methylation in FIT fluid demonstrates the opportunity to combine testing for occult blood with DNA methylation in the same collection device.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.